Establishment of the Cambridge Single Cell Analysis Clinical Core Facility [SCACCF]

最近的技术发展已经彻底改变了我们表征，量化和分离单细胞的能力。在诊断和治疗后以单细胞分辨率检查疾病，将通过提高患者诊断质量，改进治疗方案，监测对治疗的反应以及检测耐药性的出现来改变分子医学的实践。剑桥的科学家一直处于单细胞表达谱和循环肿瘤DNA分析基础研究的最前沿，并建立了开发新型单细胞技术的本地生物技术公司。在这里，我们建议使用MRC基础设施的资金来创建一个新的单细胞分析共享核心设施（剑桥单细胞分析临床核心设施[SCACCF]），该设施将服务于剑桥的所有主要分子医学项目：癌症，神经科学，免疫和炎症，传染病，干细胞和再生医学，代谢医学和实验治疗学。SCACCF将成为英国的中心，并将与我们在剑桥地区的杰出战略合作伙伴（Babraham研究所，Wellcome Trust桑格研究所，欧洲生物信息学研究所，MRC分子生物学实验室，主要制药和生物技术）密切合作，使他们的不同能力承担临床研究的挑战。

Recent technology developments have revolutionised our ability to characterize, quantify and isolate single cells. Examination of diseases at single cell resolution, both at diagnosis and after treatment, will transform the practice of molecular medicine by improving the quality of patient diagnosis, refining treatment options, monitoring of response to treatment, and detecting the emergence of resistance to treatment. Cambridge scientists have been at the forefront of basic research in single cell expression profiling and the analysis of circulating tumour DNA, as well as setting up local Biotech companies that develop novel single cell technologies. Here we propose to use MRC Infrastructure funding to create a new shared core facility for single cell analysis (the Cambridge Single Cell Analysis Clinical Core Facility [SCACCF]), which will serve all major molecular medicine programmes in Cambridge: cancer, neurosciences, immunity and inflammation, infectious diseases, stem cell and regenerative medicine, metabolic medicine and experimental therapeutics. SCACCF will be well placed to act as a hub for the UK and will work closely with our outstanding strategic partners in the Cambridge area (Babraham Institute, Wellcome Trust Sanger Institute, the European Bioinformatics Institute, the MRC Laboratory for Molecular Biology, major pharma & biotech), to bring their different capabilities to bear on clinical research challenges.